Introduction
In October 1988, routine immunisation against mumps was introduced in the United Kingdom as a combined measles, mumps, and rubella (MMR) vaccine for children aged 12-15 months. Although the incidence of mumps declined quickly, mathematical modelling supported the introduction of a second dose of MMR in 1996.
1 In 1999, numbers of cases of mumps in teenagers in England and Wales began to rise. We report a further increase in the incidence of mumps in 2004. These individuals would have missed the opportunity for mumps exposure during childhood because high coverage in younger children had reduced circulation of mumps in the UK. Older individuals are more likely to have had mumps when it was still a common childhood infection. The absence of cases in children in younger cohorts, including those affected by the fall in MMR coverage since 1995, 4 confirms the effectiveness of the current vaccination policy.
Participants, methods, and results

Notifications
The mumps component of the MMR vaccine used in the UK is believed to offer around 90% protection for one dose, although recent reports indicate that this could be as low as 64%. 5 This outbreak confirms that the current, two dose MMR schedule is effective in preventing mumps. In addition to improving routine coverage of MMR, reviewing the vaccination status of all school leavers is recommended, to ensure that they have received two doses of MMR. Other opportunities to offer MMR vaccine to the age group at highest risk, such as when entering university or other institutions, should also be considered. 1 9 7 0 1 9 7 2 1 9 7 4 1 9 7 6 1 9 7 8 1 9 8 0 1 9 8 2 1 9 8 4 1 9 8 6 1 9 8 8 1 9 9 0 1 9 9 2 1 9 9 4 1 9 9 6 1 9 9 8 2 0 0 0 What is already known about this topic 
Methods and results
Counts of admissions, taken as the first consultant episode in a hospital stay, in patients aged ≤ 18 years with a main diagnosis of Crohn's disease in England (population 50 million) were available for the 12 years from April 1991 to March 2003. w1 I restricted the analysis to emergency admissions as these were probably less susceptible to changes in thresholds for admission and clinical practice than elective admissions. In the first two years of the MMR vaccination programme, the percentages of children completing a primary course of MMR vaccine in their second year of life were 7% and 68%; thereafter the percentage was at least 84%. Initially, temporal trends in age specific rates were plotted, differentiating between the rates for those born before and after the introduction of the vaccine. (Rates for patients aged 16 to 18 years-too old to have been offered the vaccine as infants-provided information on underlying trends unaffected by MMR vaccination in infancy.) Data for those born in 1987-8, of whom only 68% were vaccinated as infants, were excluded from the analysis. The MMR vaccination programme was then modelled as a variable with two levels (vaccination rate of ≥ 84% and of ≤ 7%) using Poisson regression, with adjustment for year of admission and age in single years (as categorical variables).
There were 4463 admissions for Crohn's disease, 923 of which occurred in populations with a vaccination rate of ≥ 84% (those born in 1988-9 or later). Although the age specific rates increased over the study period, no obvious changes occurred that coincided with the introduction of MMR vaccine (figure). The estimated rate ratio for the MMR vaccination programme (rates in populations with a vaccination rate of ≥ 84% compared with those with a rate of ≤ 7%) was 0.95 (95% confidence interval 0.84 to 1.08).
